Print Page  Close Window


SEC Filings

8-K
OREXIGEN THERAPEUTICS, INC. filed this Form 8-K on 10/01/2018
Entire Document
 


In re: Orexigen Therapeutics, Inc.

Debtor

  

Case No. 18-10518 (KG)

Reporting Period: August 1, 2018 - August 31, 2018

 

MOR - 3

Balance Sheet

(Unaudited)

 

     Orexigen Therapeutics, Inc.  

$ USD ‘000s

   As of March 11, 2018      As of August 31, 2018  

Assets

     

Current assets:

     

Cash and cash equivalents

   $ 21,372      $ 37,432  

Accounts receivable, net

     19,203        —    

Inventory

     8,857        —    

Prepaid expenses and other current assets

     6,868        7,994  

Intercompany receivable(1)

     93,353        —    
  

 

 

    

 

 

 

Total current assets

     149,653        45,427  

Non-current assets:

     

Property and equipment, net

     543        —    

Investment in Subsidiary(1)

     19,000        —    

Intangible assets

     66,566        —    

Other long-term assets

     588        1,643  

Restricted cash

     100        110  
  

 

 

    

 

 

 

Total assets

   $ 236,450      $ 47,180  
  

 

 

    

 

 

 

Liabilities and Stockholders’ Equity

     

Current liabilities:

     

Accounts payable (2)

     925        1,787  

DIP loan

     —          —    

Accrued expenses

     3,921        8,148  
  

 

 

    

 

 

 

Total current liabilities:

     4,846        9,934  
  

 

 

    

 

 

 

Total liabilities not subject to compromise

     4,846        9,934  

Total liabilities subject to compromise

     110,381        245,481  

Series Z preferred stock

     3,343        —    

Stockholders’ equity (deficit)

     117,880        (208,235
  

 

 

    

 

 

 

Total liabilities and stockholders’ equity (deficit)

   $ 236,450      $ 47,180  
  

 

 

    

 

 

 

Notes:

 

(1)

Investment in Subsidiary $19m reclassed from Intercompany Receivable at March 11, 2018 to properly align for reporting.

(2)

Accounts payable excludes all liabilities assumed by the purchaser under the terms of the Asset Purchase Agreement.